Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma

摘要: Aims The presence of a BRAF mutation is strong marker for poor prognosis colorectal carcinoma (CRC), and can be used as evidence sporadic mechanism mismatch repair deficiency. may also predict resistance to EGFR-targeted therapy. A V600E-specific antibody has recently become commercially available. The aim this study was determine whether immunohistochemistry mutations in CRC. Methods results Immunohistochemistry performed on 52 genotyped CRC cases (17 mutant, 18 KRAS 17 BRAF/KRAS wild-type) with monoclonal VE1. Cytoplasmic staining observed 71% V600E mutant tumours (moderate or 50% these cases). Weak cytoplasmic 17% 35% wild-type tumours. Non-specific nuclear common. sensitivity specificity VE1 were 74%, respectively; when only moderate considered positive, the 100%, but 35%. Conclusions Immunohistochemistry not useful surrogate genotyping CRC. Although specific mutations, insufficiently sensitive serve an effective screening tool.